Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis
Status:
Completed
Trial end date:
2021-03-02
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate the safety and tolerability of LEO
138559 in healthy subjects and subjects with moderate to severe atopic dermatitis.
The secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics
following administration of LEO 138559 to healthy subjects and subjects with moderate to
severe atopic dermatitis.
Healthy subjects will be exposed to 7 different dose regimens of LEO 138559 (one dose regimen
per subject).
Subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose
regimens of LEO 138559 (one dose regimen per subject).